This section hosts publications (updates, reports and guidelines) by the NHP and its network partners and affiliates.
The NHP activity report for 2023/2024 (published 21 November 2024) gives an overview of its core and partner-related activities.
Following the stepping down of Professor Baba Inusa, Dr Kate Gardner has been appointed the new NHP Chair.
Pfizer Shares Patient Advice Regarding Immediate Withdrawal of Voxelotor (Oxybryta®)
Following the unforeseen Pfizer withdrawal of Voxelotor (Oxbryta®) Medication for Sickle Cell Disease on 25th September 2024, the NHP provided a letter assist affected Sickle Cell Disorder patients.
NHS England sends a letter to centres regarding the 25.09.2024 withdrawal of Pfizer's Oxbryta (Voxelotor) drug for Sickle Cell Disorder.
University College London have produced a Standard Operating Procedure (SOP) for the assessment and work up of exagamglogene autotemcel (Casgevy™) for transfusion-dependent beta-thalassaemia
For World Sickle Cell Awareness Day (19th June) 2024, we ask; 'Why try to reinvent the wheel?'
The Founding Chair of the NHP, Professor Baba Inusa, announces his departure from the NHS and his NHP Role in March 2024.
The NHP Annual Report is a summary of its activities and interactions.
The National Haemoglobinopathy Panel
Women's and Children's Academic Health - Kings College London
Becket House
1 Lambeth Palace Rd
London, SE1 7EU
